Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension

BACKGROUND: Endothelin-receptor-antagonist, bosentan, has been found to improve the functional capacity and cardiopulmonary hemodynamics in Pulmonary Arterial Hypertension (PAH). Clinical trials have shown the preferable dosage of 125 mg, twice daily, regarding both efficacy and safety. OBJECTIVES:...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Res Cardiovasc Med
Huvudupphovsmän: Amin, Ahmad, Mohamadifar, Arezoo, Taghavi, Sepideh, Naderi, Nasim, Sadeghi, Hosnolah
Materialtyp: Artigo
Språk:Inglês
Publicerad: Kowsar 2015
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4588707/
https://ncbi.nlm.nih.gov/pubmed/26436071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5812/cardiovascmed.26487v2
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk